• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Mammalian Target of Rapamycin [mTOR] / Related Products
You are here: Product Lines > Signal Transduction > PI(3)K-Akt-mTOR Pathway > Mammalian Target of Rapamycin [mTOR] / Related Products
Toolbar - View Selection
 
Items 4 of 4
ALX-270-460 Revised 04-Sep-07
PI-103
Add to Clipboard
SYNONYMS 3-(4-(4-Morpholinyl)pyrido[3’,2’:4,5]furo[3,2-d]pyrimidin-2-yl)phenol
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Phosphoinositide 3-kinase [PI(3)K] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-460-M001   1 mg 70.00 USD Add To Cart
ALX-270-460-M005   5 mg 280.00 USD Add To Cart
ALX-270-460-M025   25 mg 980.00 USD Add To Cart
Product Specification
FORMULA: C19H16N4O3
MW: 348.4
CAS NUMBER: 371935-74-9
PURITY: ≥97% (HPLC)
APPEARANCE: Off-white solid.
SOLUBILITY: Soluble in DMSO (5mg/ml; warm).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY:

Stock solutions are stable for up to 3 months when stored at -20°C.

HANDLING: Protect from light. After reconstitution, prepare aliquots and store at -20°C.

Product Description
Potent, cell permeable and ATP-competitive inhibitor of DNA-PK, phosphoinositide 3-kinase (PI(3)K), the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. Exhibits little activity towards a panel of more than 40 other kinases even at concentrations as high as 10µM. Effectively blocks cell proliferation in glioma cell lines both in vitro and in vivo.
Product Specific Literature References
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma: Q.W. Fan, et al.; Cancer Cell 9, 341 (2006) Abstract
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling: Z.A. Knight, et al.; Cell 125, 733 (2006) Abstract
Further Categories Containing This Product:
Mammalian Target of Rapamycin [mTOR] / Related Products
 
 
ALX-210-142 Revised 12-Jun-06
Polyclonal Antibody to FKBP12
Add to Clipboard
SYNONYMS anti-FK506 Binding Protein (12kDa) PAb
PRODUCT LINE Immunology
PRODUCT CATEGORY Immunophilins / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-210-142-R100   100 µl 379.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
Rat
SOURCE/HOST: From rabbit.
CONCENTRATION: 1mg/ml.
PURITY DETAIL: Epitope-affinity purified IgG.
FORMULATION: Liquid. In PBS containing 1mg/ml BSA and 0.05% sodium azide.
IMMUNOGEN: Synthetic peptide corresponding to aa 1-13 (G1VQVETISPGDGR13) of human FKBP12 (FK506 binding protein 12kDa).
SPECIFICITY: Recognizes human, mouse and rat FKBP12. Detects a band of ~12kDa by Western blot.
APPLICATION: Immunohistochemistry (frozen sections (2µg/ml); paraffin sections)
Immunoprecipitation
Western Blot (1µg/ml)
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
BLOCKING PEPTIDE: For Blocking Peptide see Prod. No. ALX-156-002.
Product Images
Please click on thumbnails to enlarge.
Product Specific Literature References
The effects of FK506 on retinal ganglion cells after optic nerve crush: E.E. Freeman and C.L. Grosskreutz; IOVS 41, 1111 (2000) Abstract
Immunophilin expression in the HIV-infected brain: C.L. Achim, et al.; J. Neuroimmunol. 157, 126 (2004) Abstract
Further Categories Containing This Product:
Mammalian Target of Rapamycin [mTOR] / Related ProductsPolyclonal Antibodies
 
 
ALX-210-065 Revised 10-Dec-04
Polyclonal Antibody to mTOR
Add to Clipboard
SYNONYMS anti-Mammalian Target of Rapamycin PAb
anti-FRAP1 PAb
anti-RAFT1 PAb
anti-RAPT1 PAb
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY Mammalian Target of Rapamycin [mTOR] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-210-065-C050   50 µg 220.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Rat
SOURCE/HOST: From rabbit.
CONCENTRATION: 12mg/ml
FORMULATION: Liquid. Protein G purified antibody in PBS containing 10% glycerol and 0.02% sodium azide.
IMMUNOGEN: Human mTOR (mammalian target of rapamycin) (aa 1223-1290).
SPECIFICITY: Recognizes human and rat mTOR.
APPLICATION: Immunoprecipitation (1-5µg)
Western Blot (1µg/ml)
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
Product Specific Literature References
Identification of TOR signaling complexes: more TORC for the cell growth engine: R.T. Abraham; Cell 111, 9 (2002) Abstract
Further Categories Containing This Product:
Polyclonal Antibodies
 
 
ALX-380-004 Revised 21-Feb-08
Rapamycin
Add to Clipboard
SYNONYMS Sirolimus
AY-22,989
RAPA
Rapamune
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Immunomodulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-004-C100   100 µg 35.00 USD Add To Cart
ALX-380-004-5100   5x100 µg 90.00 USD Add To Cart
ALX-380-004-M001   1 mg 120.00 USD Add To Cart
ALX-380-004-M005   5 mg 420.00 USD Add To Cart
ALX-380-004-M025   25 mg 950.00 USD Add To Cart
Product Specification
FORMULA: C51H79NO13
MW: 914.2
CAS NUMBER: 53123-88-9
MERCK INDEX: 14: 8114
RTECS: VE6250000
SOURCE/HOST: Isolated from Streptomyces hygroscopicus.
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in chloroform, DMSO or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: TOXIC.

Product Description
Macrocyclic-triene antibiotic possessing potent immunosuppressant activity. It forms a complex with FKBP12 that binds to an effector, thus inhibiting IL-2 and other growth promoting lymphokines. The effectors were recently identified as FRAP (FKBP12 rapamycin-associated protein) and RAFT1 (rapamycin and KFBP12 target). Rapamycin induces inhibition of p70s6k, p33cdk2 and p34cdc2. Enhances apoptosis.
Product Specific Literature References
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle: C. Vezina, et al.; J. Antibiot. (Tokyo) 28, 721 (1975) Abstract
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization: S.N. Sehgal, et al.; J. Antibiot. (Tokyo) 28, 727 (1975) Abstract
Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase: D.J. Price, et al.; Science 257, 973 (1992) Abstract
Rapamycin: in vitro profile of a new immunosuppressive macrolide: S.N. Sehgal & C.C. Bansback; Ann. N. Y. Acad. Sci. 685, 58 (1993) Abstract
Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes: W.G. Morice, et al.; J. Biol. Chem. 268, 22737 (1993) Abstract; Full Text
A mammalian protein targeted by G1-arresting rapamycin-receptor complex: E.J. Brown, et al.; Nature 369, 756 (1994) Abstract
RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin- dependent fashion and is homologous to yeast TORs: D.M. Sabatini, et al.; Cell 78, 35 (1994) Abstract
Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells: S. Muthukkumar, et al.; Transplantation 60, 264 (1995) Abstract
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro: Y. Shi, et al.; Cancer Res. 55, 1982 (1995) Abstract
Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells: T. Ishizuka, et al.; BBRC 230, 386 (1997) Abstract
Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells: S.M. Metcalfe, et al.; Oncogene 15, 1635 (1997) Abstract
Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability: S. Hashemolhosseini, et al.; J. Biol. Chem. 273, 14424 (1998) Abstract; Full Text
Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells: H. Hosoi, et al.; Cancer Res. 59, 886 (1999) Abstract
Rapamycin: an anti-cancer immunosuppressant?: B.K. Law; Crit. Rev. Oncol. Hematol. 56, 47 (2005), Review Abstract
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours: B. Ory, et al.; Curr. Med. Chem. 14, 1381 (2007), Review Abstract
 
 

Your items will be kept only for the duration of your visit.